Establishment and Characterization of Carboplatin-Resistant Retinoblastoma Cell Lines. 2022

Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul 03080, Korea.

Carboplatin-based chemotherapy is the primary treatment option for the management of retinoblastoma, an intraocular malignant tumor observed in children. The aim of the present study was to establish carboplatin-resistant retinoblastoma cell lines to facilitate future research into the treatment of chemoresistant retinoblastoma. In total, two retinoblastoma cell lines, Y79 and SNUOT-Rb1, were treated with increasing concentrations of carboplatin to develop the carboplatin-resistant retinoblastoma cell lines (termed Y79/CBP and SNUOT-Rb1/CBP, respectively). To verify resistance to carboplatin, the degree of DNA fragmentation and the expression level of cleaved caspase-3 were evaluated in the cells, following carboplatin treatment. In addition, the newly developed carboplatin-resistant retinoblastoma cells formed in vivo intraocular tumors more effectively than their parental cells, even after the intravitreal injection of carboplatin. Interestingly, the proportion of cells in the G0/G1 phase was higher in Y79/CBP and SNUOT-Rb1/CBP cells than in their respective parental cells. In line with these data, the expression levels of cyclin D1 and cyclin D3 were decreased, whereas p18 and p27 expression was increased in the carboplatin-resistant cells. In addition, the expression levels of genes associated with multidrug resistance were increased. Thus, these carboplatin-resistant cell lines may serve as a useful tool in the study of chemoresistance in retinoblastoma and for the development potential therapeutics.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012175 Retinoblastoma A malignant tumor arising from the nuclear layer of the retina that is the most common primary tumor of the eye in children. The tumor tends to occur in early childhood or infancy and may be present at birth. The majority are sporadic, but the condition may be transmitted as an autosomal dominant trait. Histologic features include dense cellularity, small round polygonal cells, and areas of calcification and necrosis. An abnormal pupil reflex (leukokoria); NYSTAGMUS, PATHOLOGIC; STRABISMUS; and visual loss represent common clinical characteristics of this condition. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2104) Glioblastoma, Retinal,Glioma, Retinal,Neuroblastoma, Retinal,Eye Cancer, Retinoblastoma,Familial Retinoblastoma,Hereditary Retinoblastoma,Sporadic Retinoblastoma,Cancer, Retinoblastoma Eye,Cancers, Retinoblastoma Eye,Eye Cancers, Retinoblastoma,Familial Retinoblastomas,Glioblastomas, Retinal,Gliomas, Retinal,Hereditary Retinoblastomas,Neuroblastomas, Retinal,Retinal Glioblastoma,Retinal Glioblastomas,Retinal Glioma,Retinal Gliomas,Retinal Neuroblastoma,Retinal Neuroblastomas,Retinoblastoma Eye Cancer,Retinoblastoma Eye Cancers,Retinoblastoma, Familial,Retinoblastoma, Hereditary,Retinoblastoma, Sporadic,Retinoblastomas,Retinoblastomas, Familial,Retinoblastomas, Hereditary,Retinoblastomas, Sporadic,Sporadic Retinoblastomas
D016190 Carboplatin An organoplatinum compound that possesses antineoplastic activity. cis-Diammine(cyclobutanedicarboxylato)platinum II,Blastocarb,CBDCA,Carboplat,Carbosin,Carbotec,Ercar,JM-8,NSC-241240,Nealorin,Neocarbo,Paraplatin,Paraplatine,Platinwas,Ribocarbo,JM 8,JM8,NSC 241240,NSC241240
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D053148 Caspase 3 A short pro-domain caspase that plays an effector role in APOPTOSIS. It is activated by INITIATOR CASPASES such as CASPASE 9. Isoforms of this protein exist due to multiple alternative splicing of its MESSENGER RNA. CASP3,Apopain,Caspase-3,Pro-Caspase-3,Procaspase-3,Pro Caspase 3,Procaspase 3
D056743 Cyclin D3 A broadly expressed type D cyclin. Experiments using KNOCKOUT MICE suggest a role for cyclin D3 in LYMPHOCYTE development.
D019572 Retinal Neoplasms Tumors or cancer of the RETINA. Cancer of the Retina,Cancer, Retinal,Neoplasms, Retinal,Retinal Cancer,Retinal Tumors,Tumors, Retinal,Cancers, Retinal,Neoplasm, Retinal,Retinal Cancers,Retinal Neoplasm,Retinal Tumor,Tumor, Retinal
D019938 Cyclin D1 Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms. CCND1 Protein,PRAD1 Protein,Proto-Oncogene Proteins c-bcl-1,bcl-1 Proto-Oncogene Proteins,c-bcl-1 Proteins,Proto-Oncogene Products bcl-1,Proto-Oncogene Protein bcl-1,bcl-1 Proto-Oncogene Products,bcl1 Proto-Oncogene Proteins,Proto Oncogene Products bcl 1,Proto Oncogene Protein bcl 1,Proto Oncogene Proteins c bcl 1,Proto-Oncogene Products, bcl-1,Proto-Oncogene Proteins, bcl-1,Proto-Oncogene Proteins, bcl1,bcl 1 Proto Oncogene Products,bcl 1 Proto Oncogene Proteins,bcl-1, Proto-Oncogene Protein,bcl1 Proto Oncogene Proteins,c bcl 1 Proteins,c-bcl-1, Proto-Oncogene Proteins

Related Publications

Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
January 1993, Anticancer research,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
March 2010, Anticancer research,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
March 2018, Oncotarget,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
February 2023, Advanced biology,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
April 2012, International journal of oncology,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
March 1988, International journal of cancer,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
June 2010, Medical science monitor : international medical journal of experimental and clinical research,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
January 2024, Theriogenology,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
August 2015, Molecular medicine reports,
Chang Sik Cho, and Dong Hyun Jo, and Jin Hyoung Kim, and Jeong Hun Kim
December 1978, National Cancer Institute monograph,
Copied contents to your clipboard!